The biopharmaceutical company has chosen the regulated market of Euronext Paris for an operation of at least 25 million euros. It intends to convince investors of the potential of a new generation of drugs for brain diseases, including cannabis-related disorders, or cognitive deficits, such as Down's syndrome. Increasing the concentration of THC...